Bone Therapeutics Looks To ALLOB Data Progress
Executive Summary
Following its IPO in 2015, Belgium's Bone Therapeutics has been making progress on its allogeneic osteoblastic cell product, ALLOB, which recently appointed CEO Thomas Lienard pegs as the company's most valuable platform. With the product currently in Phase II trials, Lienard shares his plans for the company.